Trialists Grapple with How to Outsmart TREM2
After one TREM2 agonist antibody nose-planted, a new batch of therapies appear safe so far in first-in-human data. The drugs exert different effects on the receptor and soluble TREM2.
ALL NEWS
6654 RESULTS
Sort By:
- Most Recent
- Most Commented
TREM2: A Chill Pill for Neurons?
In mouse models, the microglial receptor counteracts hyperexcitability. Both transmembrane and soluble TREM2 seem involved.
Moving Target: New Biology Casts TREM2 as a Shifty Mark
TREM2 on plaque-associated microglia becomes desensitized to agonist antibodies. The receptor may also calm hyperactive neurons.
New Partnership Forms to Harness AI for Alzheimer’s Research
Drawing in researchers in academia, pharma, and AI companies, a nascent consortium aims to speed up discoveries in complex diseases. Smaller AI projects report data at AD/PD.
Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s
Several tracers detect the low level of α-synuclein aggregates present in sporadic disease. None are ready for clinical use.
Zapping the Zoster Virus, Dodging Dementia
Among people vaccinated against shingles in Wales, there were 20 percent fewer dementia diagnoses over the next seven years.
AD/PD™ 2025: Advances in Science & Therapy
Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s New Partnership Forms to Harness AI for Alzheimer’s Research Moving Target: New Biology Casts TREM2 as a Shifty Mark TREM2: A Chill Pill for Neurons? Trialists Grapple with How to
Tau-PET and P-tau217—Equally Predictive, Yet Complementary
In a head-to-head comparison, the two markers similarly predicted cognitive decline in healthy people. Still, using them sequentially might best identify who will benefit from therapy.
Do Synaptic Markers Foreshadow Cognitive Decline?
Ratio of two peptides in cerebrospinal fluid increases with age, a change accelerated by Alzheimer’s disease.
Donanemab Clinical Use Growing in U.S., Rejected in Europe
Donanemab prescriptions have been slow to ramp up, but demand is growing due to an easier dosing schedule than for lecanemab.
Plaque Removal Delays Onset of Familial Alzheimer’s Disease
Healthy people who carry an autosomal-dominant AD mutation halved their odds of developing symptoms when they took gantenerumab for eight years.
Filling in the Family Tree: AD, CTE Folds Spotted in Other Tauopathies
Core structures of protofilaments from more diseases prompt an update to the family tree of tau filaments.
Is Dementia Incidence Still Dropping? Birth Cohort Data Say Yes.
Dementia prevalence has come down nearly 3 percent per year for the last 40 years, with each successive birth cohort less likely to succumb.
Mobile Devices Track Brain Health in 23,000 People
In the largest study of its kind, volunteers took cognitive tests on their devices and had their app usage monitored. Baseline data flagged people with MCI.
Eat Well, Stay Trim—Your Brain Will Thank You Later
People who ate a healthy diet and carried less abdominal fat in midlife had better-working brains 20 years later, according to MRI scans.
Current Filters
No filters selected